Every client responds differently, but many individuals begin noticing changes in appetite within the first few weeks of treatment
![i just took my first dose of semaglutide Week 1 on Ozempic [My & Why Im Starting This Journey] Is 50 units of semaglutide](https://framerusercontent.com/images/MpfCZyEVFKwDRneTXuYPqpAeY.jpg?width=1024&height=572)
Approval Timeline and Availability CagriSema: Ahead in the Race FDA Submission: December 18, 2025 (NDA filed) Expected FDA Decision: Q4 2026 or Q1 2027 Predicted Launch: Mid-2027 Advantage: 6-12 month head start on retatrutide REDEFINE Program Status: REDEFINE-1: Completed (obesity, 20.4% weight loss) REDEFINE-2: Completed (type 2 diabetes, 13.7% weight loss) REDEFINE-3: Ongoing (cardiovascular outcomes trial) REDEFINE-8: Ongoing (body composition study) High-dose CagriSema (2.4/7.2mg): Starting late 2026 Retatrutide: More Trials Needed FDA Submission: Expected Q4 2026 or Q1 2027 Expected FDA Decision: Late 2027 Predicted Launch: Q1-Q2 2028 TRIUMPH Program Status: TRIUMPH-4: Completed (osteoarthritis, 28.7% weight loss) TRIUMPH-1: Complete 28.3% weight loss (May 2026) TRIUMPH-2: Expected Q3Q4 2026 (obesity + type 2 diabetes) TRIUMPH-3: Expected later 2026 (obesity + cardiovascular disease) TRIUMPH-6: Weight maintenance trial (ongoing) Disadvantage: Needs more trials before submission, 6-12 month delay vs CagriSema
![i just took my first dose of semaglutide Week 1 on Ozempic [My & Why Im Starting This Journey] Is 50 units of semaglutide](https://freemedicaljournals.com/blog/wp-content/uploads/2026/05/How-Many-mg-Is-40-Units-of-Semaglutide-683x1024.png)
We also recommend that people ensure vitamin C intake is adequate, as glutathione (GSH) and vitamin C work synergistically to help protect our body from oxidative stress (inflammation)
Association of bariatric surgery with cardiovascular outcomes in adults with severe obesity and nonalcoholic fatty liver disease
Novo Nordisk is hoping to inject fresh momentum into Wegovy's sales growth with a just-awarded first-in-class approval in metabolic dysfunction-associated steatohepatitis (MASH), a disease which affects millions of people worldwide